

RECEIVED  
CENTRAL FAX CENTER

Attorney Docket No.: 5573.210-US

AUG 10 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peschke et al.

Serial No.: 09/356,313  
Group Art Unit: 1653

Filed: July 16, 1999  
Examiner: D. Lukton

For: Compounds With Growth Hormone Releasing Properties

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Petition to Issue a Corrected Patent

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner D. Lukton, fax number (571)273-8300.

Respectfully submitted,

Date: August 10, 2007

  
Karen Schlauch  
Novo Nordisk Inc.  
Customer No. 23650  
(609)987-5800

RECEIVED  
CENTRAL FAX CENTER

AUG 10 2007

Attorney Docket No.: 5573.210-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peschke et al.

Confirmation No.: 7669

Application No.: 09/356,313

Group Art Unit: 1653

Filed: July 16, 1999

Examiner: Lukton, David

For: Compounds With Growth Hormone Releasing Properties

## PETITION TO ISSUE A CORRECTED PATENT

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

U.S. Patent No.: US 6,919,315 issued July 19, 2005. Applicant notes the issued claims do not include the amendments to the claims that were submitted November 12, 2004, and acknowledged by Examiner Lukton as entered in a Notice of Allowability mailed January 7, 2005, and reiterated in an Amendment Under 37 C.F.R. § 1.312 submitted February 8, 2005, and acknowledged as entered by Examiner Lukton in the Response to Rule 312 Communication mailed May 27, 2005.

Applicant encloses herewith the most recent Claim Listing, which was submitted February 8, 2005, containing the amendments as accepted by Examiner Lukton.

Due to the extensive nature of the corrections necessary and the fact that the error is entirely a mistake on the part of the USPTO, Applicant respectfully requests the Director issue a Corrected Patent in lieu of a Certificate of Correction pursuant to 37 C.F.R. § 1.322(b).

Applicant believes there should be no fees incurred with this petition. However should there be a fee necessary to facilitate this process, please charge any required fee for this petition and credit any overpayments to Novo Nordisk Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447.

Respectfully submitted,

Date: August 10, 2007



Rosemarie R. Wilk-Orescan  
Registration Number 45,220  
Customer Number 23650  
(609) 987-5969

**Use the following customer number for all correspondence regarding this application.**

23650

PATENT TRADEMARK OFFICE